Description:

Z1041: Study Drug Completion - FEC-75/Paclitaxel (SDCFP) NCT00513292 Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=20FE4AE7-E041-0F11-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=20FE4AE7-E041-0F11-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/9/15
  3. 6/21/15
Uploaded on:

June 21, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Z1041: Study Drug Completion - FEC-75/Paclitaxel (SDCFP) NCT00513292

No Instruction available.

  1. StudyEvent: Z1041: Study Drug Completion - FEC-75/Paclitaxel (SDCFP)
    1. No Instruction available.
Header Module
Visit
Assessment of Chemotherapy
Agent name (FEC-75 was given, complete:)
Agent name (FEC-75 was given, complete:)
Were there any dose modifications or additions/omissions to protocol treatment?
Dose Modification Reason (If yes, )

Similar models